Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα

Cell Death & Differentiation volume 30, pages 1320–1333 (2023)Cite this article

Subjects

Abstract

Acute promyelocytic leukemia (APL) is driven by the oncoprotein PML-RARα, which recruits corepressor complexes, including histone deacetylases (HDACs), to suppress cell differentiation and promote APL initiation. All-trans retinoic acid (ATRA) combined with arsenic trioxide (ATO) or chemotherapy highly improves the prognosis of APL patients. However, refractoriness to ATRA and ATO may occur, which leads to relapsed disease in a group of patients. Here, we report that HDAC3 was highly expressed in the APL subtype of AML, and the protein level of HDAC3 was positively associated with PML-RARα. Mechanistically, we found that HDAC3 deacetylated PML-RARα at lysine 394, which reduced PIAS1-mediated PML-RARα SUMOylation and subsequent RNF4-induced ubiquitylation. HDAC3 inhibition promoted PML-RARα ubiquitylation and degradation and reduced the expression of PML-RARα in both wild-type and ATRA- or ATO-resistant APL cells. Furthermore, genetic or pharmacological inhibition of HDAC3 induced differentiation, apoptosis, and decreased cellular self-renewal of APL cells, including primary leukemia cells from patients with resistant APL. Using both cell line- and patient-derived xenograft models, we demonstrated that treatment with an HDAC3 inhibitor or combination of ATRA/ATO reduced APL progression. In conclusion, our study identifies the role of HDAC3 as a positive regulator of the PML-RARα oncoprotein by deacetylating PML-RARα and suggests that targeting HDAC3 could be a promising strategy to treat relapsed/refractory APL.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: HDAC3 is highly expressed in the APL subtype, and inhibition of HDAC3 suppresses APL progression by inducing apoptosis and differentiation of APL cells.
Fig. 2: Inhibition of HDAC3 suppresses APL progression and produces a synergistic effect with ATRA.
Fig. 3: Inhibition of HDAC3 induces PML-RARα degradation by enhancing ubiquitination.
Fig. 4: HDAC3-mediated PML-RARα deacetylation interferes with PML-RARα ubiquitination and degradation.
Fig. 5: Inhibition of HDAC3 induces differentiation and apoptosis in drug-resistant APL cells by degrading PML-RARα mutations.
Fig. 6: Inhibition of HDAC3 relieves APL in animal models inoculated with drug-resistant APL cells.
Fig. 7: Schematic diagram illustrating the mechanism by which APL is relieved through HDAC3 inhibition.

Data availability

The dataset analyzed during this study can be accessed using the GEO with accession GSE13204. All the other data supporting the findings of this study are available within the article and its supplementary information files and from the corresponding author upon reasonable request.

References

  1. de The H, Pandolfi PP, Chen Z. Acute promyelocytic leukemia: a paradigm for oncoprotein-targeted cure. Cancer Cell. 2017;32:552–60.

    Article  PubMed  Google Scholar 

  2. Zhu J, Zhou J, Peres L, Riaucoux F, Honore N, Kogan S, et al. A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell. 2005;7:143–53.

    Article  CAS  PubMed  Google Scholar 

  3. Chen ZH, Wang WT, Huang W, Fang K, Sun YM, Liu SR, et al. The lncRNA HOTAIRM1 regulates the degradation of PML-RARA oncoprotein and myeloid cell differentiation by enhancing the autophagy pathway. Cell Death Differ. 2017;24:212–24.

    Article  CAS  PubMed  Google Scholar 

  4. Xu HE, Stanley TB, Montana VG, Lambert MH, Shearer BG, Cobb JE, et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα. Nature. 2002;415:813–7.

    Article  CAS  PubMed  Google Scholar 

  5. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N. Engl J Med. 2013;369:111–21.

    Article  CAS  PubMed  Google Scholar 

  6. Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science (N. Y, NY). 2010;328:240–3.

    Article  CAS  Google Scholar 

  7. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2004;101:5328–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia: 3 decades of development. Blood. 2009;113:3655–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Rochette-Egly C, Germain P. Dynamic and combinatorial control of gene expression by nuclear retinoic acid receptors (RARs). Nucl Recept Signal. 2009;7:e005.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2017;35:605–12.

    Article  CAS  Google Scholar 

  11. Kayser S, Schlenk RF, Platzbecker U. Management of patients with acute promyelocytic leukemia. Leukemia. 2018;32:1277–94.

    Article  PubMed  Google Scholar 

  12. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002;1:287–99.

    Article  CAS  PubMed  Google Scholar 

  13. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol. 2008;9:206–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Zhu J, Chen Z, Lallemand-Breitenbach V, de Thé H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002;2:705–13.

    Article  CAS  PubMed  Google Scholar 

  15. Zhou J, Pérès L, Honoré N, Nasr R, Zhu J, de Thé H. Dimerization-induced corepressor binding and relaxed DNA-binding specificity are critical for PML/RARA-induced immortalization. Proc Natl Acad Sci USA. 2006;103:9238–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Karagianni P, Wong J. HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene. 2007;26:5439–49.

    Article  CAS  PubMed  Google Scholar 

  17. Zhang J, Kalkum M, Chait BT, Roeder RG. The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2. Mol Cell. 2002;9:611–23.

    Article  CAS  PubMed  Google Scholar 

  18. Mehdipour P, Santoro F, Botrugno OA, Romanenghi M, Pagliuca C, Matthews GM, et al. HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemia. Leukemia. 2017;31:995–7.

    Article  CAS  PubMed  Google Scholar 

  19. Moretti S, Abdel-Aziz AK, Ceccacci E, Pallavicini I, Santoro F, de Thé H, et al. Co-targeting leukemia-initiating cells and leukemia bulk leads to disease eradication. Leukemia. 2022;36:1306–12.

  20. Long J, Jia MY, Fang WY, Chen XJ, Mu LL, Wang ZY, et al. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia. Blood. 2020;135:1472–83.

    Article  PubMed  Google Scholar 

  21. Rabellino A, Carter B, Konstantinidou G, Wu SY, Rimessi A, Byers LA, et al. The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA. Cancer Res. 2012;72:2275–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Shao X, Chen Y, Wang W, Du W, Zhang X, Cai M, et al. Blockade of deubiquitinase YOD1 degrades oncogenic PML/RARα and eradicates acute promyelocytic leukemia cells. Acta Pharm Sin B. 2022;12:1856–70.

  23. Hu C, Peng K, Wu Q, Wang Y, Fan X, Zhang DM, et al. HDAC1 and 2 regulate endothelial VCAM-1 expression and atherogenesis by suppressing methylation of the GATA6 promoter. Theranostics. 2021;11:5605–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Long J, Fang WY, Chang L, Gao WH, Shen Y, Jia MY, et al. Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response. Leukemia. 2017;31:2761–70.

    Article  CAS  PubMed  Google Scholar 

  25. Li K, Wang F, Cao WB, Lv XX, Hua F, Cui B, et al. TRIB3 promotes APL progression through stabilization of the oncoprotein PML-RARalpha and inhibition of p53-mediated senescence. Cancer cell. 2017;31:697–710.e697.

    Article  CAS  PubMed  Google Scholar 

  26. Hu J, Zhang H, Li J, Jiang X, Zhang Y, Wu Q, et al. ROCK1 activation-mediated mitochondrial translocation of Drp1 and cofilin are required for arnidiol-induced mitochondrial fission and apoptosis. J Exp Clin Cancer Res. 2020;39:37.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Deng X, Liu J, Liu L, Sun X, Huang J, Dong J. Drp1-mediated mitochondrial fission contributes to baicalein-induced apoptosis and autophagy in lung cancer via activation of AMPK signaling pathway. Int J Biol Sci. 2020;16:1403–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Nguyen HCB, Adlanmerini M, Hauck AK, Lazar MA. Dichotomous engagement of HDAC3 activity governs inflammatory responses. Nature. 2020;584:286–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol. 2008;10:547–55.

    Article  CAS  PubMed  Google Scholar 

  30. Goto E, Tomita A, Hayakawa F, Atsumi A, Kiyoi H, Naoe T. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood. 2011;118:1600–9.

    Article  CAS  PubMed  Google Scholar 

  31. de The H, Le Bras M, Lallemand-Breitenbach V. The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies. J Cell Biol. 2012;198:11–21.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Minucci S, Nervi C, Lo Coco F, Pelicci PG. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene. 2001;20:3110–5.

    Article  CAS  PubMed  Google Scholar 

  33. Matthews GM, Mehdipour P, Cluse LA, Falkenberg KJ, Wang E, Roth M, et al. Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. Blood. 2015;126:2392–403.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Zhu J, Gianni M, Kopf E, Honoré N, Chelbi-Alix M, Koken M, et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci USA. 1999;96:14807–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Wang X, Lin Q, Lv F, Liu N, Xu Y, Liu M, et al. LG-362B targets PML-RARalpha and blocks ATRA resistance of acute promyelocytic leukemia. Leukemia. 2016;30:1465–74.

    Article  CAS  PubMed  Google Scholar 

  36. Lu Y, Yan JS, Xia L, Qin K, Yin QQ, Xu HT, et al. 2-Bromopalmitate targets retinoic acid receptor alpha and overcomes all-trans retinoic acid resistance of acute promyelocytic leukemia. Haematologica. 2019;104:102–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Zhu HH, Qin YZ, Huang XJ. Resistance to arsenic therapy in acute promyelocytic leukemia. N Engl J Med. 2014;370:1864–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by grants from the National Key R&D Program of China (2022YFA1106100), the National Natural Science Foundation of China (81770187, 82170149, 82222070, 82273973, 81872904, 82073887, 82073711 and 82003798), the CAMS Innovation Fund for Medical Sciences (2021-I2M-1-030, 2022-I2M-2-002 to KL; 2021-I2M-1-070 to TTZ) and the Fundamental Research Funds for the Central Universities (2022-RC350-07, 3332022149).

Author information

Author notes

  1. These authors contributed equally: Bo Dai, Feng Wang, Ying Wang.

Authors and Affiliations

  1. Shanghai Institute of Hematology, Blood and Marrow Transplantation Center, Collaborative Innovation Center of Hematology, Department of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Rd, Shanghai, 200025, China

    Bo Dai, Ying Wang, Jiayan Zhu, Lining Wang, Wenhui Gao, Junmin Li & Jiong Hu

  2. NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Tian Tan Xi Li, Beijing, 100050, China

    Bo Dai, Feng Wang, Yunxuan Li, Tingting Zhang, Luyao Zhao & Ke Li

  3. Department of Hematology, Huashan Hospital, Fudan University, Shanghai, 200040, China

    Bo Dai

  4. Department of Hematology, Tong Ji Hospital, Tong Ji University School of Medicine, No 389 Xincun Road, Shanghai, 200065, China

    Ying Wang

  5. Department of Hematology, The First Affiliated Hospital, College of Medicine, and Institute of Hematology, Zhejiang University, Zhejiang, 310003, China

    Honghu Zhu

Authors
  1. Bo Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Feng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ying Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiayan Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yunxuan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tingting Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Luyao Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lining Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wenhui Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Junmin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Honghu Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ke Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Jiong Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JH, KL, BD, and FW designed the overall study and wrote the manuscript; BD and YW performed experiments and analyzed data; JZ, YL, and TZ helped with animal experiments; LZ, LW and WG helped to collect patients’ primary samples; JL and HZ provided advice and reviewed the manuscript.

Corresponding authors

Correspondence to Ke Li or Jiong Hu.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval

The study was approved by the Institutional Review Board of the Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. All animal procedures were approved by the Institutional Committee for the Ethics of Animal Care and Treatment in Biomedical Research of Chinese Academy of Medical Sciences and PUMC.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dai, B., Wang, F., Wang, Y. et al. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα. Cell Death Differ 30, 1320–1333 (2023). https://doi.org/10.1038/s41418-023-01139-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41418-023-01139-8

Search

Advanced search

Quick links